Jafron Biomedical Co.,Ltd. (SHE:300529)
China
· Delayed Price · Currency is CNY 18.71
-0.27 (-1.42%)
At close: Mar 9, 2026
Jafron Biomedical Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Operating Revenue | 2,030 | 2,670 | 1,919 | 2,487 | 2,671 | 1,946 | Upgrade
|
| Other Revenue | 7.33 | 7.33 | 3.42 | 4.54 | 4.5 | 4.64 | Upgrade
|
| Revenue | 2,038 | 2,677 | 1,922 | 2,491 | 2,675 | 1,951 | Upgrade
|
| Revenue Growth (YoY) | -22.58% | 39.27% | -22.84% | -6.88% | 37.15% | 36.24% | Upgrade
|
| Cost of Revenue | 427.5 | 520.26 | 390.89 | 440.36 | 402.12 | 288 | Upgrade
|
| Gross Profit | 1,610 | 2,157 | 1,531 | 2,051 | 2,273 | 1,663 | Upgrade
|
| Selling, General & Admin | 739.61 | 881.19 | 787.89 | 838.78 | 729.46 | 587.45 | Upgrade
|
| Research & Development | 212.41 | 240.09 | 245.38 | 253.91 | 173.77 | 80.76 | Upgrade
|
| Other Operating Expenses | 77.96 | 37.29 | 24.61 | 33.72 | 39.56 | 28.24 | Upgrade
|
| Operating Expenses | 1,019 | 1,159 | 1,048 | 1,124 | 949.55 | 697.27 | Upgrade
|
| Operating Income | 591.55 | 997.98 | 482.98 | 926.66 | 1,324 | 965.51 | Upgrade
|
| Interest Expense | -56 | -63.71 | -54.33 | -36.04 | -8.91 | - | Upgrade
|
| Interest & Investment Income | 41.51 | 73.09 | 87.96 | 63.79 | 56.5 | 44.01 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.78 | 0.78 | 1.22 | 1.07 | -0.81 | -0.37 | Upgrade
|
| Other Non Operating Income (Expenses) | 28.19 | -1.73 | -2.12 | -0.5 | -5.34 | -2.36 | Upgrade
|
| EBT Excluding Unusual Items | 606.03 | 1,006 | 515.71 | 954.97 | 1,365 | 1,007 | Upgrade
|
| Impairment of Goodwill | -5.2 | -5.2 | -25.61 | -6.26 | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | 31.61 | 1.02 | - | -0.01 | 0.01 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | -1.58 | 3.64 | 6.72 | 0.86 | 0.98 | - | Upgrade
|
| Asset Writedown | -9.29 | -1.04 | -1.46 | -1.61 | -1.15 | -0.48 | Upgrade
|
| Other Unusual Items | -17.18 | 2.13 | 25.66 | 68.85 | 42.14 | 25.64 | Upgrade
|
| Pretax Income | 604.4 | 1,007 | 521.02 | 1,017 | 1,407 | 1,032 | Upgrade
|
| Income Tax Expense | 127.18 | 192.78 | 95.3 | 135.86 | 211.38 | 158.95 | Upgrade
|
| Earnings From Continuing Operations | 477.22 | 814.19 | 425.72 | 880.95 | 1,196 | 873 | Upgrade
|
| Minority Interest in Earnings | 4.57 | 6.01 | 10.77 | 8.62 | 0.97 | 2.24 | Upgrade
|
| Net Income | 481.79 | 820.2 | 436.49 | 889.56 | 1,197 | 875.24 | Upgrade
|
| Net Income to Common | 481.79 | 820.2 | 436.49 | 889.56 | 1,197 | 875.24 | Upgrade
|
| Net Income Growth | -40.11% | 87.91% | -50.93% | -25.67% | 36.74% | 53.33% | Upgrade
|
| Shares Outstanding (Basic) | 758 | 781 | 794 | 794 | 803 | 796 | Upgrade
|
| Shares Outstanding (Diluted) | 765 | 781 | 794 | 794 | 803 | 810 | Upgrade
|
| Shares Change (YoY) | -3.68% | -1.57% | -0.08% | -1.12% | -0.89% | 2.22% | Upgrade
|
| EPS (Basic) | 0.64 | 1.05 | 0.55 | 1.12 | 1.49 | 1.10 | Upgrade
|
| EPS (Diluted) | 0.63 | 1.05 | 0.55 | 1.12 | 1.49 | 1.08 | Upgrade
|
| EPS Growth | -37.82% | 90.91% | -50.89% | -24.83% | 37.96% | 50.00% | Upgrade
|
| Free Cash Flow | 578.69 | 815.85 | 669.49 | 407.91 | 712 | 600.37 | Upgrade
|
| Free Cash Flow Per Share | 0.76 | 1.04 | 0.84 | 0.51 | 0.89 | 0.74 | Upgrade
|
| Dividend Per Share | 0.800 | 0.800 | 0.400 | 0.670 | 0.900 | 0.660 | Upgrade
|
| Dividend Growth | 100.00% | 100.00% | -40.30% | -25.56% | 36.36% | 39.33% | Upgrade
|
| Gross Margin | 79.02% | 80.57% | 79.67% | 82.33% | 84.97% | 85.24% | Upgrade
|
| Operating Margin | 29.03% | 37.28% | 25.12% | 37.19% | 49.48% | 49.49% | Upgrade
|
| Profit Margin | 23.64% | 30.64% | 22.71% | 35.70% | 44.73% | 44.87% | Upgrade
|
| Free Cash Flow Margin | 28.40% | 30.47% | 34.83% | 16.37% | 26.61% | 30.78% | Upgrade
|
| EBITDA | 736.68 | 1,120 | 573.43 | 995.72 | 1,373 | 1,002 | Upgrade
|
| EBITDA Margin | 36.15% | 41.82% | 29.83% | 39.97% | 51.32% | 51.38% | Upgrade
|
| D&A For EBITDA | 145.13 | 121.69 | 90.44 | 69.07 | 49.25 | 36.73 | Upgrade
|
| EBIT | 591.55 | 997.98 | 482.98 | 926.66 | 1,324 | 965.51 | Upgrade
|
| EBIT Margin | 29.03% | 37.28% | 25.12% | 37.19% | 49.48% | 49.49% | Upgrade
|
| Effective Tax Rate | 21.04% | 19.14% | 18.29% | 13.36% | 15.02% | 15.40% | Upgrade
|
| Revenue as Reported | 2,038 | 2,677 | 1,922 | 2,491 | 2,675 | 1,951 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.